Avalo Therapeutics 'Represents An Attractive Pure-Play,' Analyst Initiates Coverage With Over 300% Stock Upside

On Monday, Stifel initiated coverage on Avalo Therapeutics, Inc. AVTX. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb targeting inflammatory diseases.The company initiated a Phase 2 LOTUS trial, which will include approximately 180 adults with hidradenitis suppurativa (HS), to evaluate the efficacy and safety of subcutaneous bi-weekly and monthly dosing regimens compared to placebo. Topline data is expected in 2026.Avalo continues to evaluate AVTX-009 for additional immune-mediated diseases with plans to ...